Related Experiment Video
Updated: Aug 25, 2026
Models of Bone Metastasis
Published on: September 4, 2012
Evaluation of models for steroid-protein interactions in malignancy
1King's College School of Medicine and Dentistry, Department of Surgery, Rayne Institute, London, England.
Abstract:
Over the past two decades many model systems have been proposed for the steroid-protein interaction in target cells. The most widely used two-step model in malignant tissue is now seriously questioned. With the advent of advancing methodology and monoclonal antibodies the new models support nuclear localisation of the receptor, the clinical significance of this in cancer treatment is far from clear. These latter models are not without drawbacks themselves. Immunological, and immunocytochemical techniques in particular, cannot provide full binding parameters on receptor status, its affinity for a steroid, the number and nature of binding sites. Thus the ligand binding assay still remains useful and in combination with immunological techniques should provide information that neither technique can provide alone. This approach has great promise in the evaluation of receptor status in cancer. The interactions of steroids with intracellular non-steroid proteins and receptor-independent phenomena are indicative of the complexities that the designers of models will have to contend with.
Insights
Current steroid-protein interaction models for cancer are challenged. Combining ligand binding assays with immunological techniques offers a promising approach for evaluating receptor status in cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Steroid-protein interactions are crucial in target cells, with various models proposed over two decades.
- The widely accepted two-step model for malignant tissues is now under scrutiny.
- Advancements in methodology and monoclonal antibodies have led to new models emphasizing nuclear receptor localization.
Purpose of the Study:
- To evaluate the limitations of current steroid-protein interaction models in cancer.
- To explore the potential of combining different techniques for a more comprehensive understanding of receptor status.
- To address the complexities in modeling steroid-protein interactions for improved cancer treatment strategies.
Main Methods:
- Review of existing steroid-protein interaction models, including the two-step model and newer nuclear localization models.
- Discussion of the limitations of immunological and immunocytochemical techniques in providing full binding parameters.
- Highlighting the continued utility of ligand binding assays.
Main Results:
- Newer models supporting nuclear receptor localization have unclear clinical significance in cancer treatment.
- Immunological techniques alone cannot fully characterize receptor status, affinity, or binding sites.
- Ligand binding assays remain essential for determining binding parameters.
Conclusions:
- Combining ligand binding assays with immunological techniques offers a powerful approach for evaluating receptor status in cancer.
- This integrated approach promises to provide comprehensive information that neither technique can offer alone.
- Complexities such as interactions with non-steroid proteins and receptor-independent phenomena must be considered in future model development.
